This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): cell culture-derived influenza vaccine, Optaflu (EU)
Description: Flucelvax is a “subunit” influenza virus vaccine prepared from virus propagated in Madin Darby Canine Kidney (MDCK) cells, a continuous cell line. The viral strains incorporated in the vaccine vary from year to year according to which have been identified by the USPHS as likely to be most prevalent. Flucelvax contains no adjuvant.
Novartis completed its acquisition of Chiron (including its vaccines) in April 2006.
Novartis and CSL
In October 2014, Novartis entered into a definitive agreement to divest its influenza vaccines business to CSL Limited (CSL) for an agreed price of USD 275 million. This transaction requires regulatory approvals and is expected to close in the second half of 2015.
In August 2015, CSL announced that it has closed ts transaction to acquire Novartis global influenza vaccine business for a cash consideration of US$275 million.
Additional information available to subscribers only: